Medimpact

STANDARD COMMERCIAL DRUG FORMULARY PRIOR AUTHORIZATION GUIDELINES

FENTANYL TRANSDERMAL PATCH

Generic	Brand	HICL	GCN	Strength	Exception/Other
FENTANYL	DURAGESIC		24635	12MCG/HR	GPID ≠ 25879
			19200	25MCG/HR	ROUTE =
			37952	37.5MCG/HR	TRANSDERM.
			19201	50MCG/HR	
			37947	62.5MCG/HR	
			19202	75MCG/HR	
			37948	87.5MCG/HR	
			19203	100MCG/HR	

GUIDELINES FOR USE

1. Does the patient meet the definition of opioid tolerance (defined as those who are taking, for one week or longer, at least 60mg oral morphine per day, 25mcg transdermal fentanyl/hour, 30mg oral oxycodone/day, 25mg oral oxymorphone/day, 8mg oral hydromorphone/day, or an equianalgesic dose of another opioid)?

If yes, continue to #2. If no, do not approve. **DENIAL TEXT:** See the denial text at the end of the guideline.

2. Does the request form indicate that this medication will be used on an "as needed" or "PRN" basis?

If yes, do not approve. **DENIAL TEXT:** See the denial text at the end of the guideline. If no, continue to #3.

3. Is the request for more than one strength of transdermal fentanyl patch OR does the patient have an active prior authorization(s) for a different strength of fentanyl patch?

If yes, send to Clinical Pharmacist for review. If no, continue to #4.

4. Is the request for every 72 hours dosing?

If yes, approve for 12 months with the following quantity limits:

• FOR EVERY 72 HOUR DOSING: (12, 25, 37.5, 50, 62.5, 75, 87.5mcg/hr) approve by GPID for #10 patches per 30 days.

• FOR 100mcg/hr: approve by GPID (100mcg/hr) for up to #20 patches per 30 days. (NOTE: Please override both PA and step therapy [if applicable] restrictions by entering 'Y' for OVR_RES).

If no, continue to #5.

CONTINUED ON NEXT PAGE

Copyright © 2019 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Medimpact

STANDARD COMMERCIAL DRUG FORMULARY PRIOR AUTHORIZATION GUIDELINES

FENTANYL TRANSDERMAL PATCH

GUIDELINES FOR USE (CONTINUED)

5. Is the request for dosing every 48 hours?

If yes, continue to #6. If no, send to Clinical Pharmacist for review.

6. Has the patient tried every 72 hours dosing?

If yes, approve for 12 months with the following quantity limits:

• FOR EVERY 48 HOUR DOSING: (12, 25, 37.5, 50, 62.5, 75, 87.5mcg/hr) approve by GPID for #15 patches per 30 days.

• FOR 100mcg/hr: approve by GPID (100mcg/hr) for up to #30 patches per 30 days. (NOTE: Please override both PA and step therapy [if applicable] restrictions by entering 'Y' for OVR_RES).

If no, do not approve.

DENIAL TEXT: The guideline named **FENTANYL TRANSDERMAL PATCH (Duragesic)** requires that the patient meets the following criteria:

- The patient meets the definition of opioid tolerance (defined as those who are taking, for one week or longer, at least 60mg oral morphine per day, 25mcg transdermal fentanyl/hour, 30mg oral oxycodone/day, 25mg oral oxymorphone/day, 8mg oral hydromorphone/day, or an equianalgesic dose of another opioid)
- The requested medication is not prescribed on an 'as needed' basis
- Requests for dosing every 48 hours requires a trial of transdermal fentanyl dosed every 72 hours

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Duragesic.

REFERENCES

• Fentanyl Patch [Prescribing Information]. Morgantown, WV: Mylan Pharmaceuticals, Inc.; March 2015.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A Commercial Effective: 10/01/19 Created: 02/03 Client Approval: 08/19

P&T Approval: 07/19

Copyright © 2019 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.